Kornimate/medical-research-clean huggingface dataset:
sirt1(rs7069102 ) gene polymorphism in chronic obstructive pulmonary disease at egyptian patients

Conditions: Genotyping of SIRT1in Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease (copd) prevalence, morbidity, and mortality vary across countries and across different groups within countries with a direct relation to the prevalence of tobacco smoking. other risk factors for copd include genetic factors, longstanding asthma, outdoor air pollution, second-hand smoke exposure, biomass smoke, indoor air pollution, occupational exposures, and tuberculosis . the prevalence and burden of copd are projected to increase in the coming decades because of continued exposure to copd risk factors and the changing age structure of the world's population. as these factors are rapidly increasing in developing countries, copd will become a major health problem, exerting a huge demand on economic and healthcare resources in developing countries \[2\]. in egypt, although copd is a rising significant health problem, data on its prevalence, morbidity, and mortality are still lacking and have to be estimated . sirtuin 1 (sirt1) is a protein/histone deacetylase dependent nad. it plays a crucial role in various human diseases such as cardiovascular diseases, cancer, inflammation, aging, neurodegenerative disease, obesity and type 2 diabetes. seven isoforms of the sirt1 gene (sirt1- sirt7) have been determined in mammals. expression of the sirt1 gene is regulated by transcription factors such as creb, foxo3, hic1, nf-kb, p53, parp-2 and ppar. sirt1


Eligibility criteria:
inclusion criteria: * all patients admitted to sohag university hospital, chest department. exclusion criteria: * patients with malignancies, any other chronic disease, individuals with a history of known chronic cardiorespiratory diseases and those with collagen vascular diseases were excluded.
development and needs assessment and efficiency of smart communication system for patients with als (part 2)

Conditions: Amyotrophic Lateral Sclerosis

Summary: the research is aimed to asses the validity of the communication system improving the quality of life and the degree of sanctification of clinical patients and their caregiver.


Eligibility criteria:
inclusion criteria: * escorial revised criteria (brooks et al., 2000),the diagnosis of als requires: (a) the presence of: * (a:1) evidence of lower motor neuron (lmn) degeneration by clinical, electrophysiological or neuropathologic examination (a:2) evidence of upper motor neuron (umn) degeneration by clinical examination, and * (a:3) progressive spread of symptoms or signs within a region or to other regions, as determined by history or examination, together with: (b) the absence of (b:1) electrophysiological or pathological evidence of other disease processes that might explain the signs of lmn and/or umn degeneration, and (b:2) neuroimaging evidence of other disease processes that might explain the observed clinical and electrophysiological signs. * if they were taiwanese and used traditional chinese(mandarin). * if they were older than age 20 years. exclusion criteria: * if they had been diagnosed with frontotemporal dementia, severe depression, or schizophrenia. * if they cannot see the communication board after correction. * if they cannot complete the questionnaire with researchers or family members help.

Keywords: amyotrophic lateral sclerosis, als, communication, needs
budesonide for induction of remission in incomplete microscopic colitis

Conditions: Incomplete Microscopic Colitis

Summary: the purpose of this study is to demonstrate the efficacy of budesonide for the treatment of active incomplete microscopic colitis.


Eligibility criteria:
inclusion criteria: * histologically established diagnosis of incomplete microscopic colitis (mci) * history of chronic non-bloody, watery diarrhoea * clinically active disease exclusion criteria: * other significant abnormalities in colonoscopy * infectious cause of diarrhoea * clinical suspicion of drug-induced diarrhoea * prior and present mc * history of bowel resection * radiation therapy of the abdominal or pelvic region * positive antibody titres for celiac disease * untreated active thyroid dysfunction * any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder reducing life expectancy * abnormal hepatic function * tuberculosis, hypertension, diabetes mellitus, osteoporosis, peptic ulcer disease, glaucoma, cataract, or infection if careful medical monitoring is not ensured * history of colorectal cancer * history of cancer (other than colorectal) in the last 5 years * therapy with immunomodulators/budesonide or other steroids/antibiotics/anti-diarrhoeal drugs * current or intended pregnancy or breast-feeding * doubt about the patient's cooperation, e.g. because of addiction to alcohol or drugs * participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial
the effect of education hemodialysis patients according to roy adaptation model

Conditions: Hemodialysis

Summary: the study was conducted in order to evaluate the effect of the training provided to hemodialysis patients according to roy adaptation model on fluid management, symptom control, and quality of life. the study was carried out as a randomized controlled trial with the participation of 107 patients (53 experimental, 54 control) the patients in the experimental group were provided with training based on roy adaptation model, and training booklets were handed out.the control group did not attempt any intervention.

the most difficult domain for hemodialysis patients is fluid-salt restriction. patients with inadequate fluid compliance/adherence experience many symptoms that negatively affect their life. the study was carried out as a randomized controlled trial with the participation of 107 patients (53 experimental, 54 control). the data were collected by using "patient information from", "fluid control in hemodialysis patients scale" (fchps), "dialysis symptom index" (dsi), and "nottingham health profile" (nhp). the forms were filled out by having interviews with the patients in the experimental and control groups in the 0th, 1st, and 3rd months. the patients in the experimental group were provided with training based (face to face individual) on roy adaptation model (0th(onset)and 1st month), and training booklets were handed out. the training was about 30-45 minutes. control group did not attempt any intervention. routine maintenance of the control and experimental group and continued. when comparing the experimental and control groups, onset 0th month, 1st month and 3rd month measurements were taken into consideration. all scales were administered to the experimental and control groups at month 0 (onset), 1 and 3 months. the data were analyzed by using descriptive statistics methods with ncss (number cruncher statistical system) 2007 software, student's t-test, mann-whitney u test, pearson chi-square test, fisher-freeman-halton exact test, repeated measures test, bonferroni testi significance was accepted as p\<0,05.

Eligibility criteria:
inclusion criteria: patients with end-stage chronic kidney disease older than 18 years undergoing routine hemodialysis treatment for at least 3 months having 3 hemodialysis sessions literate volunteered to participate in the study exclusion criteria: patients with acute renal failure previously diagnosed with liver failure and/or malignancy ,patients with new york heart society class 3-4 heart failure a history of kidney transplantation

Keywords: fluid management,symptom control,life quality
evaluation of an automated physician-directed messaging on patient engagement in the digital diabetes prevention program

Conditions: Pre Diabetes

Summary: this study aims to understand the effects of automated physician directed messaging on patient engagement in the digital diabetes prevention program (ddpp). the messages are tailored to patient engagement levels based on established engagement thresholds, which are based on the patient's use of the ddpp application. the system is designed to minimize work for providers by sending automated targeted messages to patients to potentially increase engagement, prevent onset of diabetes and improve clinical outcomes. the patients in the study are automatically nudged using a combination of text messaging and mychart messaging.

using a mixed-methods design, this study will be completed in three phases. for phase 3, we aim to conduct a randomized control trial with 400 patients with pre-diabetic, all of whom will be using the ddpp application. half of enrolled patients will be randomized to the intervention group and receive automated targeted messaging.

Eligibility criteria:
inclusion criteria: * 18 years or older, bmi ≥ 25 kg/m2 (\> 22 kg/m2 if self-identified as asian) * must be a nyu langone patient * a diagnosis of prediabetes (either diagnosis of prediabetes or an hba1c level of 5.7%-6.4% in past 12 months) or diabetes risk factors (bmi ≥ 25 kg/m2 or \> 22 kg/m2 if self-identified as asian * safe to engage in moderate physical exercise (as determined by their pcp) * sufficient english to be able to complete the enrollment process * has app-capable device with data to use the ddpp application and receive text messages exclusion criteria: * diagnosed with diabetes * patients whose weight may vary considerably over the study's timeframe for reasons other than the intervention (e.g. cancer, pregnancy, ascites, severe chf) * patients with severe psychiatric disease or dementia * active health condition that prevents them from engaging in moderate exercise
arrhythmia in on pump vs. off pump coronary artery bypass grafting

Conditions: Ischemic Heart Disease

Summary: the aim of this research is to know the incidence of arrhythmias in on vs. off pump cabg and to know their relations to the patient's morbidity and mortality, hospital stay and hospital costs.

on pump vs. off pump cabg has been a topic of debate for many years regarding the benefits and the risks of each technique .off pump cabg began 30 years ago. its promotion was based on its potential benefits over some of the limitation of traditional on pump cabg. it avoids the trauma of cardiopulmonary bypass (cpb) and minimizing aortic manipulation and reducing length of hospital stay and morbidity. there is a criticism regarding completence of revascularization in off pump vs. on pump cabg, this is no longer valid in the current era as technology to safely perform multi vessel off pump has improved tremendously over the past decade. one of the debates between these two techniques was the incidence of arrhythmias in and after the operation and its relation to morbidity and mortality at the operation and hospital stay after the operation. as known atrial fibrillation (af) is still the most common arrhythmia that occur after cabg and although in some studies it has been considered a benign and self-limiting complication, some suggest serious morbidity and mortality from this complication, it is said that it affects more than 40% of patients underwent cabg. atrial fibrillation (af) may lead to thromboembolic complications, additional pharmacotherapy, longer hospital stay, increase cost, anxiety and stroke. most af post cabg are found in the second to third post-operative day. so, on this study the investigators focus one the incidence of arrhythmias, especially af in those two techniques and their relations to patients' morbidity and mortality.

Eligibility criteria:
inclusion criteria: * all patients subjected to cabg exclusion criteria: * associated valvular heart disease * emergency cases * previous af
imaging with a pet agent for detection of cancers of the head and neck

Conditions: Head and Neck Cancer

Summary: the purpose of this study is to test the safety of a study drug called parpi-fl. this drug has been tested in animals but not yet in people. the purpose of this study is to test if a parpi-fl scan can be used to take pictures of head and neck cancer. the usual approach to imaging this cancer includes several different imaging scans, including x-rays, ct (computed tomography), mri (magnetic resonance imaging), and pet (positron emission tomography). these tests take pictures of the cancer.


Eligibility criteria:
inclusion criteria: part 1: * age ≥18 years * ecog performance status 0 or 1 * biopsy (histologically or cytologically) proven squamos cell carcinoma * oral cavity, oropharynx, or nasopharynx primary site * at least one tumor lesion on standard of care imaging with a minimum diameter of at least 1.5 cm * scheduled to undergo treatment at mskcc * willingness to sign informed consent part 2 * age ≥18 years * ecog performance status 0 or 1 * biopsy (histologically or cytologically) proven squamous cell carcinoma * oral cavity,oropharynx, or nasopharynx primary site * scheduled to undergo surgery (neck dissection and/ or neck dissection + surgical removal of the primary) at msk * willingness to sign informed consent * should have had a standard-of-care \[18f\]-fdg pet/ct scan before surgery (to minimize the possibility of new alterations developing between the two scans both scans should be acquired within a maximum time difference of one month). exclusion criteria: * significantly impaired organ function that may interfere with the excretion and metabolism of the imaging agent. specifically, patients will be excluded if they meet the following criteria: * hematologic o platelets \<75k/mcl * hepatic * bilirubin \>2.0 x uln (institutional upper limits of normal) * ast/alt \>2.5 x uln * renal o creatinine \> 2.0 x uln * claustrophobia interfering with pet/ct imaging * known allergy to peg300 * pregnancy or breastfeeding

Keywords: radiation dosimetry of [18f]parpi pet/ct scans
effect of interleukin-1 receptor antagonist on inhalation of 20,000 eu clinical ctr reference endotoxin in normal volunteers

Conditions: Healthy Control Subjects

Summary: the investigators want to see if healthy people who are given 2 doses of a medication called anakinra, which is used to treat moderate to severe rheumatoid arthritis, (ra) and then exposed to a form of air pollution, called endotoxin, have less inflammation with the medication. endotoxin is believed to be one of the causes of asthma attacks.


Eligibility criteria:
inclusion criteria: * healthy volunteers * age 18-50 years exclusion criteria: * asthma * pregnant women * smokers

Keywords: healthy volunteer endotoxin
eczema action plan improves patient and caregiver understanding and perception of atopic dermatitis management

Conditions: Atopic Dermatitis

Summary: this is a randomized controlled study. the control group will consist of adult subjects and the caregivers of pediatric subjects with an established diagnosis of atopic dermatitis (ad), who are visiting a dermatologist for a standard ad office visit. in the control group, only verbal instruction (vi), the standard of care, will be provided. the intervention group will receive a similar vi with an additional component: an eczema education handout, as well as an individualized written eczema action plan (eap) that will illustrate how to recognize disease flare-ups and subsequent remissions. in addition, the eap will provide detailed step-wise instructions regarding treatment modifications for the above-mentioned variations in treatment severity. to ensure that all patients ultimately receive the same level of care, the control group will also receive an eap at the end of their consultation. the goal of this study is to assess subjects' perception in the provider's use of an eap and its effectiveness in helping patients understand their disease and management plan. in order to evaluate the primary end-points, subjects in both the control and treatment groups will be asked to complete post-consultation surveys. four post-consultation outcomes will be measured: (1) caregivers' understanding of the disease and treatment, (2) caregivers' comfort level in following the eap at home, (3) caregivers' anxiety level in managing the ad at home, and (4) caregivers' preference for vi + eap as compared to vi alone, eap alone, or neither the eap nor the vi.


Eligibility criteria:
inclusion criteria: * age 18 or older fulfilling hanifin and rajka diagnostic criteria for ad, or adult caregivers for patients younger than 18 years of age, and the ability to comprehend study materials in english exclusion criteria: * prior exposure to written action plans

Keywords: atopic dermatitis eczema action plan patient education written handout investigator's global assessment randomized controlled trial
a taste and acceptance study of fruitivits in children aged 4-8 years following a ketogenic diet.

Conditions: Seizure Disorders

Summary: subjects will be asked to substitute their usual vitamin and mineral supplement/s with fruitivits for seven consecutive days.

the study will involve 12 subjects between 4 and 8 years of age, who routinely use comprehensive micronutrient supplementation as part of their dietary management. primary hypothesis: fruitivits is an acceptable source of vitamin, mineral and trace elements for patients on a ketogenic diet. secondary hypothesis: fruitivits will be well accepted and tolerated when given orally to children on a ketogenic diet.

Eligibility criteria:
inclusion criteria: 1. diagnosis of condition requiring a ketogenic diet 2. currently on a ketogenic diet 3. aged 4 - 8 years 4. routinely taking a complete micronutrient supplement 5. oral feeding exclusion criteria: 1) children aged less than 4 years or older than 9 years of age
repetitive transcranial magnetic stimulation for refractory auditory hallucinations in schizophrenia

Conditions: Refractory Schizophrenia

Summary: studies using repetitive transcranial magnetic stimulation (rtms) as a treatment for refractory auditory hallucinations (ah) in schizophrenia have shown promise. the majority of studies have examined the effect of low frequency left-sided stimulation (lfl) (i.e., 1 hz) to the temporal parietal cortex (tpc). priming stimulation (6 hz) prior to lfl stimulation (hereby simply referred to as priming) has been shown to enhance the neurophysiological effects of lfl rtms alone and, as such, may lead to greater attenuation of ah. therefore, this study evaluated the efficacy of priming rtms and lfl rtms, compared to sham, applied to the tpc in patients with schizophrenia experiencing refractory auditory hallucinations (ah).


Eligibility criteria:
inclusion criteria: * voluntary and capable to consent based on the subject's ability to provide a spontaneous narrative description of the key elements of the study * have a diagnosis of schizophrenia or schizoaffective disorder as confirmed by the structured clinical interview for the dsm-iv (scid-iv) * between the ages of 18 and 65 * meet criteria for ah of at least moderate severity based on the positive and negative symptom scale (panss) * willing to keep the dose of antipsychotic stable for the duration of the study * meet criteria for medication resistance, defined as daily ah despite 2 adequate 6-week trials of at least 2 antipsychotic medications and including 1 atypical antipsychotic medication. an adequate trial is defined as a daily dose of 1000 chlorpromazine equivalents for typical antipsychotics medications and the following dosages for atypical antipsychotic medications: risperidone 6 mg, olanzapine 15 mg, quetiapine 500 mg, clozapine 300 mg. exclusion criteria: * dsm-iv history of alcohol and/or substance abuse in past month, or alcohol and/or substance dependence in the last 6 months * presence of concomitant major, unstable medical or neurologic illness, or a history of seizures * are pregnant * have received rtms for any reason in the past * have had a dose change of usual psychotropic medications in the 4 weeks preceding study entry.

Keywords: hallucinations schizophrenia
tiotropium in the treatment of the patients with chronic obstructive pulmonary disease

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: to collect post-marketing safety and effectiveness information on the use of tiotropium inhalation capsules (18 μg) in patients with chronic obstructive pulmonary disease in daily clinical settings


Eligibility criteria:
inclusion criteria: - patients with copd exclusion criteria: -there is no exclusion criterion, because this post marketing study (pms) is observational survey under condition of normal clinical practice
regulatory t-cells and crohn's disease

Conditions: Crohn Disease

Summary: aim: the main aim of this study is to investigate if immune cells (regulatory t-cells, th17 cells and other immune cell types) or biomarkers can be used to predict the response or lack of response to treatment with infliximab. if so, characteristics of the immune cells may also unveil the mechanisms behind lack of response to infliximab. design: a prospective, observational study with three arms. in the treatment group, 35 patients with crohn's disease about to start infliximab-treatment are recruited. they have blood samples drawn at day 1 before first treatment, after 6 week, and again after 22 weeks of treatment. 12 healthy volunteers serve as a control group. controls are only investigated once. all treatment and follow-up are according to national guidelines, and data from this study is not used by the clinicians. methods: the number of regulatory t-cells and pro-inflammatory t-cells (th17 cells) is investigated using flow cytometry. from plasma and serum samples, various proteins (biomarkers), such as transforming growth factor beta (tgf-beta) and tumour necrosis factor alpha (tnf-alpha), are measured using immunoassays. patient data (demographics and medical history) are extracted from various registries.

primary analyses: patient response to infliximab treatment is quantified using harvey bradshaw index, and the response is then related to the number of regulatory t-cells, th17 cells, and biomarker levels at baseline. the exact cut-off for response vs. non-respons will be determined and validated once all data is collected by an assessor blinded for the flow cytometry results and biomarker levels. plan for missing data: for patients with missing harvey bradshaw index, we will first try to re-create the score using the patient records (information on well-being, abdominal pain, diarrhea, fistulae/abscesses, and extra-intestinal crohn manifestations). if this is not possible, an experienced clinician will rate the patient's infliximab response based on all available patient record data, but blinded for flow cytometry results and biomarker levels.

Eligibility criteria:
infliximab group inclusion criteria: * crohn's disease * starting infliximab treatment * patient at the gastrointestinal department at hvidovre hospital or køge sygehus * can understand and write danish * european ancestry exclusion criteria: * not able to consent in an ethical manner (e.g. severe mental illness) * significant co-morbidity (e.g. cancer, hiv) * other immunological disease (e.g. psoriasis) * current treatment with biological agents healthy controls inclusion criteria: * no current disease * no daily drug use * can understand and write danish * european ancestry exclusion criteria: * not able to consent in an ethical manner (e.g. severe mental illness) * significant co-morbidity (e.g. cancer, hiv) * other immunological disease (e.g. psoriasis) * current treatment with biological agents

Keywords: crohn disease regulatory t-cells infliximab